vs
Side-by-side financial comparison of CorMedix Inc. (CRMD) and COMSCORE, INC. (SCOR). Click either name above to swap in a different company.
CorMedix Inc. is the larger business by last-quarter revenue ($128.6M vs $93.5M, roughly 1.4× COMSCORE, INC.). CorMedix Inc. produced more free cash flow last quarter ($92.7M vs $2.9M).
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
Comscore, Inc. is an American-based global media measurement and analytics company providing marketing data and analytics to enterprises, advertising agencies, brand marketers, and publishers.
CRMD vs SCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $128.6M | $93.5M |
| Net Profit | — | $3.0M |
| Gross Margin | 83.4% | 41.0% |
| Operating Margin | 46.0% | 7.0% |
| Net Margin | — | 3.2% |
| Revenue YoY | — | -1.5% |
| Net Profit YoY | — | -3.7% |
| EPS (diluted) | $0.20 | $9.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $128.6M | $93.5M | ||
| Q3 25 | $104.3M | $88.9M | ||
| Q2 25 | $39.7M | $89.4M | ||
| Q1 25 | $39.1M | $85.7M | ||
| Q4 24 | — | $94.9M | ||
| Q3 24 | — | $88.5M | ||
| Q2 24 | — | $85.8M | ||
| Q1 24 | — | $86.8M |
| Q4 25 | — | $3.0M | ||
| Q3 25 | $108.6M | $453.0K | ||
| Q2 25 | $19.8M | $-9.5M | ||
| Q1 25 | $20.6M | $-4.0M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | — | $-60.6M | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | 83.4% | 41.0% | ||
| Q3 25 | 89.3% | 40.6% | ||
| Q2 25 | 95.3% | 40.6% | ||
| Q1 25 | 95.9% | 39.6% | ||
| Q4 24 | — | 42.4% | ||
| Q3 24 | — | 41.2% | ||
| Q2 24 | — | 39.5% | ||
| Q1 24 | — | 42.3% |
| Q4 25 | 46.0% | 7.0% | ||
| Q3 25 | 49.2% | 1.9% | ||
| Q2 25 | 49.2% | -1.9% | ||
| Q1 25 | 51.5% | -2.4% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | -67.4% | ||
| Q2 24 | — | -2.2% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | 104.1% | 0.5% | ||
| Q2 25 | 49.9% | -10.6% | ||
| Q1 25 | 52.8% | -4.7% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | -68.5% | ||
| Q2 24 | — | -2.0% | ||
| Q1 24 | — | -1.2% |
| Q4 25 | $0.20 | $9.50 | ||
| Q3 25 | $1.26 | $-0.86 | ||
| Q2 25 | $0.28 | $-2.73 | ||
| Q1 25 | $0.30 | $-1.66 | ||
| Q4 24 | — | $-0.47 | ||
| Q3 24 | — | $-12.79 | ||
| Q2 24 | — | $-1.19 | ||
| Q1 24 | — | $-1.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $23.6M |
| Total DebtLower is stronger | — | $41.5M |
| Stockholders' EquityBook value | $405.3M | $111.4M |
| Total Assets | $826.1M | $407.7M |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $148.5M | $23.6M | ||
| Q3 25 | $55.7M | $26.7M | ||
| Q2 25 | $190.7M | $26.0M | ||
| Q1 25 | $77.5M | $31.0M | ||
| Q4 24 | — | $29.9M | ||
| Q3 24 | — | $20.0M | ||
| Q2 24 | — | $14.7M | ||
| Q1 24 | — | $18.7M |
| Q4 25 | — | $41.5M | ||
| Q3 25 | — | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | — | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $405.3M | $111.4M | ||
| Q3 25 | $374.1M | $-26.3M | ||
| Q2 25 | $220.6M | $-21.7M | ||
| Q1 25 | $114.9M | $-13.5M | ||
| Q4 24 | — | $-8.3M | ||
| Q3 24 | — | $-2.7M | ||
| Q2 24 | — | $45.8M | ||
| Q1 24 | — | $51.4M |
| Q4 25 | $826.1M | $407.7M | ||
| Q3 25 | $750.9M | $406.9M | ||
| Q2 25 | $252.6M | $415.9M | ||
| Q1 25 | $149.6M | $421.5M | ||
| Q4 24 | — | $430.2M | ||
| Q3 24 | — | $412.5M | ||
| Q2 24 | — | $474.1M | ||
| Q1 24 | — | $477.7M |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $94.5M | $3.2M |
| Free Cash FlowOCF − Capex | $92.7M | $2.9M |
| FCF MarginFCF / Revenue | 72.1% | 3.1% |
| Capex IntensityCapex / Revenue | 1.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | 1.07× |
| TTM Free Cash FlowTrailing 4 quarters | $172.8M | $21.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $94.5M | $3.2M | ||
| Q3 25 | $30.9M | $9.5M | ||
| Q2 25 | $30.0M | $932.0K | ||
| Q1 25 | $19.7M | $9.1M | ||
| Q4 24 | — | $-10.0M | ||
| Q3 24 | — | $12.5M | ||
| Q2 24 | — | $8.7M | ||
| Q1 24 | — | $6.9M |
| Q4 25 | $92.7M | $2.9M | ||
| Q3 25 | $30.4M | $9.4M | ||
| Q2 25 | $30.0M | $787.0K | ||
| Q1 25 | $19.7M | $8.7M | ||
| Q4 24 | — | $-10.3M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | 72.1% | 3.1% | ||
| Q3 25 | 29.1% | 10.5% | ||
| Q2 25 | 75.4% | 0.9% | ||
| Q1 25 | 50.5% | 10.1% | ||
| Q4 24 | — | -10.8% | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | 10.0% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | 1.3% | 0.3% | ||
| Q3 25 | 0.5% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 1.07× | ||
| Q3 25 | 0.28× | 20.96× | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | -3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
